[Federal Register Volume 84, Number 224 (Wednesday, November 20, 2019)]
[Notices]
[Pages 64080-64083]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25140]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-4626]
List of Bulk Drug Substances for Compounding Office Stock Drugs
for Use in Nonfood-Producing Animals or Antidotes for Food-Producing
Animals; Request for Nominations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for nominations.
-----------------------------------------------------------------------
[[Page 64081]]
SUMMARY: FDA is establishing a public docket for interested parties to
nominate bulk drug substances or renominate bulk drug substances that
were previously nominated without adequate supporting information, for
inclusion on a list of bulk drug substances for compounding certain
animal drugs without a patient specific prescription (i.e., office
stock) for use in nonfood-producing animals or as antidotes for food-
producing animals, as described in the draft guidance for industry
#256, ``Compounding Animal Drugs from Bulk Drug Substances,'' when that
guidance is finalized. Individuals may also comment on bulk drug
substances that have been reviewed by FDA and added to this list, or
nominations that are currently under FDA review.
DATES: You may submit either electronic or written nominations and
comments at any time.
ADDRESSES: You may submit nominations and comments by any of the
following methods.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions in the following ways:
Mail/Hand Delivery/Courier (for paper submissions):
Dockets Management Staff (HFA-305), Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2018-N-4626 for ``List of Bulk Drug Substances for Compounding
Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes
for Food-Producing Animals.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
nominations and comments received, go to https://www.regulations.gov
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT: Eric Nelson, Division of Compliance
(HFV-230), Center for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-7001,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Except with respect to the limited exemption provided by the
Federal Food, Drug, and Cosmetic Act (FD&C Act) described in the
following paragraph, statutory provisions applicable to manufactured
animal drugs under the FD&C Act also apply to animal drugs compounded
from bulk drug substances.
Sections 512(a)(4) and (5) of the FD&C Act (21 U.S.C. 360b(a)(4)
and (5)) provide a limited exemption from certain requirements for
compounded animal drugs made from already FDA-approved animal or human
drugs. Such use is considered an extralabel use. The FD&C Act provides
that a compounded drug is exempt from the approval requirements in
section 512(a) of the FD&C Act and requirements for adequate directions
for use in section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1)) if
it meets the conditions set out in the statute and the extralabel use
regulations at 21 CFR part 530.
Elsewhere in this issue of the Federal Register, FDA is announcing
the availability of draft guidance for industry #256 entitled
``Compounding Animal Drugs from Bulk Drug Substances'' (GFI #256).\1\
The draft guidance describes circumstances under which FDA, based on
our current understanding of the risks of animal drugs compounded from
bulk drug substances, does not intend to take action against
pharmacists in either State-licensed pharmacies or Federal facilities,
or veterinarians, who compound animal drugs from bulk drug substances.
If the draft guidance is finalized, FDA would not intend to take action
under sections 512(a), 501(a)(5), 502(f), and 501(a)(2)(B) of the FD&C
Act so long as such compounding is done under the approach described in
draft GFI #256.
---------------------------------------------------------------------------
\1\ Draft GFI #256 can be found at https://www.fda.gov/animal-veterinary/guidance-industry/guidance-number.
---------------------------------------------------------------------------
II. Nominating Bulk Drug Substances
In a Federal Register notice published on May 19, 2015 (80 FR
28622), FDA invited all interested parties to nominate bulk drug
substances for inclusion on a list of bulk drug substances that could
be used by outsourcing facilities registered under the FD&C Act to
compound animal drugs under the conditions described in draft GFI #230,
``Compounding Animal
[[Page 64082]]
Drugs from Bulk Drug Substances'' (announced in the same issue of the
Federal Register (80 FR 28624)) (the 2015 request for nominations
notice).
Although that draft guidance was subsequently withdrawn in November
2017, FDA received over 30 comments containing nominations for multiple
bulk drug substances in response to the 2015 request for nominations
notice. FDA's approach for evaluating whether to include a bulk drug
substance on the list described in the 2015 request for nominations
notice is substantially the same as the approach below for including a
bulk drug substance on the list of bulk drug substances for compounding
certain animal drugs without a patient specific prescription (i.e.,
office stock) for use in nonfood-producing animals or antidotes for
food-producing animals in accordance with FDA's draft guidance for
industry #256 (the List). As a result, CVM intends to include on the
List the eight bulk drug substances that FDA previously determined met
the approach set out in the now withdrawn 2015 draft guidance. To the
extent these substances and conditions of use meet the approach of the
final guidance, FDA intends to include them on the List when the draft
guidance is finalized.
Apomorphine hydrochloride--Indication: For the induction
of emesis in dogs. Dosage form: 6.25 mg subconjunctival tablets, 3.125-
6.25 milligrams/milliliters (mg/ml) subconjunctival solution, and 2.5
mg/ml injectable solution.
Cisapride--Indication: For the management of
gastrointestinal motility disorders in cats. Dosage form: 2.5 & 5 mg
oral tablets, 2.5 & 5 mg oral capsules, 5-10 mg/ml oral suspension.
Dipyrone--Indication: For the treatment of severe, acute
fever in dogs suffering from Shar-Pei Fever. Dosage form: 250 mg/ml and
500 mg/ml injectable solution.
Guaifenesin--Indication: For muscle relaxation in the
horse during anesthetic induction and/or surgery. Dosage form: 50 g
soluble powder to be reconstituted into a solution for IV infusion with
the addition of 500 ml (10%) or 1000 ml (5%) sterile diluent.
Miconazole nitrate--Indication: For the treatment of
fungal keratitis in horses. Dosage form: 1% or 2% miconazole nitrate
ophthalmic solution or ophthalmic ointment.
Potassium bromide--Indication: For initiation of treatment
for seizures in dogs. Dosage form: 250 mg/ml oral solution.
Tacrolimus--Indication: For treatment of dogs with
keratoconjunctivitis sicca that is non-responsive to cyclosporine.
Dosage form: 0.01-0.03% tacrolimus ophthalmic drops.
Metronidazole benzoate--Indication: For the treatment of
feline inflammatory bowel disease in cats. Dosage form: 80 mg/ml oral
suspension.
The docket used to collect the previous nominations is now closed
for comment. However, FDA is establishing a new public docket so that
interested parties can nominate bulk drug substances, re-nominate bulk
drug substances with adequate supporting information that were
previously nominated without adequate supporting information, or
comment on the eight previously nominated bulk drug substances that FDA
intends to add to the List when the draft guidance is finalized. This
docket will remain open indefinitely so that individuals may nominate
and comment on bulk drug substances at any time.
When will FDA include a bulk drug substance on the list of bulk drug
substances for compounding office stock drugs for use in nonfood-
producing animals or antidotes for food-producing animals?
FDA intends to include a bulk drug substance on the List when:
1. There is no marketed FDA-approved, conditionally approved, or
indexed animal drug that can be used as labeled to treat the condition;
2. There is no marketed FDA-approved animal or human drug that
could be used in an extralabel manner under section 512(a)(4) or (a)(5)
of the FD&C Act and part 530 to treat the condition;
3. The drug cannot be compounded from a legally marketed FDA-
approved, conditionally approved, or indexed animal or human drug;
4. Immediate treatment with the compounded drug is necessary to
avoid animal suffering or death; and
5. FDA has not identified a significant safety concern specific to
the use of the bulk drug substance to compound animal drugs (under the
listed conditions and limitations).
For bulk drug substances for compounding drugs intended for use as
antidotes in food-producing animals in addition to the above:
6. There is sufficient scientific information for the veterinarian
to determine appropriate withdrawal, withholding, or discard time(s)
for meat, milk, eggs, or any food which might be derived from the
treated animal(s).
How do I submit a nomination for the list?
You may submit nominations and comments to the docket through
https://www.regulations.gov. The information to support nominations can
be uploaded as attachments to your comment. The docket number is FDA-
2018-N-4626.
You may submit written submissions to the Dockets Management Staff
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All submissions must include the Docket No. FDA-
2018-N-4626 for ``List of Bulk Drug Substances for Compounding Office
Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-
Producing Animals.''
What information should I submit with the nomination?
You may nominate specific bulk drug substances for inclusion on the
List. Each bulk drug substance should be submitted to the docket as its
own, separate nomination. Submissions to the docket containing more
than one bulk drug substance will not be considered an adequate
nomination and will not be reviewed. In addition, nominations will only
be evaluated if they are for specific substances that meet the
definition of a bulk drug substance.\2\ Nominated substances that do
not meet this definition will not be evaluated for inclusion on the
List.
---------------------------------------------------------------------------
\2\ FDA regulations define ``bulk drug substance'' and ``active
pharmaceutical ingredient'' as ``any substance that is intended for
incorporation into a finished drug product and is intended to
furnish pharmacological activity or other direct effect in the
diagnosis, cure, mitigation, treatment, or prevention of disease, or
to affect the structure or any function of the body.'' The terms do
not include intermediates used in the synthesis of the substance. 21
CFR 207.1. ``Active ingredient'' is defined as ``any component that
is intended to furnish pharmacological activity or other direct
effect in the diagnosis, cure, mitigation, treatment, or prevention
of disease, or to affect the structure or any function of the body
of man or other animals. The term includes those components that may
undergo chemical change in the manufacture of the drug product and
be present in the drug product in a modified form intended to
furnish the specified activity or effect.'' 21 CFR 210.3(b)(7). Any
component other than an active ingredient is an ``inactive
ingredient'' (21 CFR 210.3(b)(8)). Inactive ingredients used in
compounded drug products commonly include flavorings, dyes,
diluents, or other excipients. In addition, for purposes of
evaluating nominations, FDA considers bulk chemicals used to make
antidotes intended to treat toxicoses in animals to be bulk drug
substances.
---------------------------------------------------------------------------
For FDA to evaluate a bulk drug substance for inclusion on the
List, you should submit the following information about the bulk drug
substance and the compounded animal drug in the nomination:
1. Confirmation That the Nominated Substance is a Bulk Drug
Substance: A
[[Page 64083]]
statement that the nominated substance meets the definition of bulk
drug substance.
2. Description of the Bulk Drug Substance:
(a) Chemical name(s);
(b) common name(s);
(c) chemical grade (e.g., USP-NF, ACS, etc.);
(d) description of the strength, stability, purity; and
(e) how the bulk drug substance is supplied (e.g., powder, liquid).
3. Description of the Animal Drugs That Will be Compounded With the
Bulk Drug Substance:
(a) dosage form(s) into which the bulk drug substance will be
compounded (e.g., capsule, tablet, suspension);
(b) strength(s) of the compounded drug(s); and
(c) intended route(s) of administration of the compounded drug(s).
4. Information Requested for FDA to Evaluate Bulk Drug Substances
for Inclusion on the List:
(a) the species and condition(s) that the drug to be compounded
with the nominated bulk drug substance is intended to treat;
(b) a bibliography of scientific literature containing safety and
effectiveness data for the drug compounded using the nominated
substance;
(c) a list of animal drugs, if any, that are FDA-approved,
conditionally approved, or indexed for the condition(s) in the species
that the drug compounded with the nominated substance is intended to
address;
(d) if there are marketed FDA-approved, conditionally approved, or
indexed drugs that address the same condition(s) in the same species,
an explanation, supported by relevant scientific literature or other
evidence, of why a compounded drug is necessary (e.g., why the FDA-
approved, conditionally approved, or indexed drug is not suitable for a
particular animal population);
(e) confirmation, using supporting evidence, that there are no
marketed FDA-approved animal or human drugs that could be prescribed in
an extralabel manner under section 512(a)(4) and (a)(5) of the FD&C Act
and 21 CFR part 530 to treat the condition(s) in the species that the
drug compounded with the nominated substance is intended to address;
(f) If the bulk drug substance is an active ingredient in a
marketed FDA-approved, conditionally approved, or indexed animal or
human drug, an explanation, supported by appropriate scientific data or
information, of why the animal drug cannot be compounded from the
marketed FDA-approved, conditionally approved, or indexed animal or
human drug.
(g) An explanation, supported by relevant scientific literature or
other evidence, of why the animal drug to be compounded with the
nominated bulk drug substance must be available to the veterinarian for
immediate treatment to avoid animal suffering or death. Nominations
should include specific information documenting that animal suffering
or death will result if treatment is delayed until a compounded animal
drug can be obtained pursuant to a prescription for an individually
identified animal; and
(h) A description of any human user or animal safety concerns
associated with use of the nominated bulk drug substance or finished
compounded drug for the condition(s) in the species that the compounded
drug is intended to address. If there are concerns, an explanation,
supported by scientific literature or other evidence, of why the
concerns should not preclude inclusion of that bulk drug substance on
the List.
(i) For compounded drugs intended for use as antidotes to treat
toxicoses in food-producing animals, relevant scientific literature or
other evidence that demonstrates that the prescribing veterinarian has
a basis for determining appropriate withdrawal, withholding, or discard
time(s) for meat, milk, eggs, or any food which might be derived from
the treated animal(s).
Dated: November 14, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-25140 Filed 11-19-19; 8:45 am]
BILLING CODE 4164-01-P